GeoVax Sponsors 2025 Dr. David Satcher Global Health Equity Summit to Advance Vaccine Access

GeoVax, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit, hosted by Morehouse School of Medicine. The summit, taking place October 2, 2025, in Atlanta, Georgia, convenes global health experts, policymakers, researchers, community organizations, and students to address pressing challenges in health equity under the theme "The Quest for Health Equity & Justice: A Glocal Perspective." This year's agenda focuses on scaling local innovations, policies, and partnerships globally to close equity gaps in healthcare access.

The 2025 Summit features keynote speaker Dr. John N. Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, alongside distinguished leaders from academic, government, and private sectors. Sessions will explore critical topics including vaccine access and trust, innovations in pandemic preparedness, and community-driven models for health equity. GeoVax's participation underscores the importance of bridging scientific advancement with equitable distribution, particularly for vulnerable populations.

Representing GeoVax at the Summit is Mary Hauser, PhD, Director of Preclinical Research, who will be available throughout the event to discuss the Company's vaccine and immunotherapy programs. Dr. Hauser will highlight GeoVax's work advancing MVA-based vaccines designed to meet the needs of immunocompromised and underserved populations, emphasizing the Company's commitment to translating scientific innovation into real-world accessibility. David Dodd, Chairman & CEO of GeoVax, stated, "Health equity is not just a goal - it is a mandate for global progress. We are honored to support the Satcher Summit and partner with Morehouse School of Medicine in advancing solutions that ensure lifesaving vaccines and therapies reach those most in need."

GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, evaluated as a primary vaccine for immunocompromised patients, a booster for those with chronic lymphocytic leukemia, and a more robust booster for healthy patients who previously received mRNA vaccines. The Company is also developing a vaccine targeting Mpox and smallpox, anticipating progression directly to Phase 3 clinical evaluation based on recent EMA regulatory guidance. For more information about GeoVax's clinical trials and updates, visit https://www.geovax.com.

The Dr. David Satcher Global Health Equity Summit, founded in honor of Dr. David Satcher, the 16th Surgeon General of the United States and Founding Director of the Satcher Health Leadership Institute, provides a platform for advancing health equity through research, innovation, and policy. Now in its third year, the event serves as a catalyst for collaboration and action to achieve sustainable change in global and community health, aligning with GeoVax's mission to ensure equitable access to vaccines and health innovations worldwide.